FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133695493> ?p ?o ?g. }

• W3133695493 endingPage "1202" @default.
• W3133695493 startingPage "1195" @default.
• W3133695493 abstract "We retrospectively collected clinical data on 31 relapsed or refractory acute myeloid leukemia (R/R AML) patients who were treated with outpatient glasdegib and low-dose Cytarabine (LDAraC) at our institution. The median age was 67 years (45–86). The median Eastern Cooperative Oncology Group performance status was 2 (1–3). The patients had previously received a median number of 2 (1–4) treatment lines, 61% (19/31) had been treated with intensive chemotherapy, 29% (9/31) had relapsed after allogeneic stem cell transplantation, and 45% (14/31) had had venetoclax exposure. Adverse cytogenetics were identified in 45% (14/31) of the cases. The CR + CRp rate was 21% (6/29) among evaluable patients. The median overall survival was 3.9 months for all patients. Different median overall survival times were observed in responders, patients achieving stable disease and those diagnosed with progressive disease: not reached vs 3.9 months vs 0.8 months, respectively (p < 0.001). The most common adverse events were pneumonia (29%, 9/31), sepsis (23%, 7/31), and febrile neutropenia (16%, 5/31). Glasdegib + LDAraC is a fairly safe, non-intensive, outpatient regimen inducing complete remission and resulting in prolonged survival in some R/R AML patients." @default.
• W3133695493 created "2021-03-15" @default.
• W3133695493 creator A5011277749 @default.
• W3133695493 creator A5017935090 @default.
• W3133695493 creator A5034255404 @default.
• W3133695493 creator A5037701749 @default.
• W3133695493 creator A5038221843 @default.
• W3133695493 creator A5049045971 @default.
• W3133695493 creator A5049132694 @default.
• W3133695493 creator A5053623055 @default.
• W3133695493 creator A5058893012 @default.
• W3133695493 creator A5075222101 @default.
• W3133695493 date "2021-03-04" @default.
• W3133695493 modified "2023-10-01" @default.
• W3133695493 title "Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients" @default.
• W3133695493 cites W1185299649 @default.
• W3133695493 cites W2097110139 @default.
• W3133695493 cites W2131593570 @default.
• W3133695493 cites W2269814587 @default.
• W3133695493 cites W2559537906 @default.
• W3133695493 cites W2887055543 @default.
• W3133695493 cites W2905344869 @default.
• W3133695493 cites W2906939534 @default.
• W3133695493 cites W2912558146 @default.
• W3133695493 cites W2928182532 @default.
• W3133695493 cites W2931348767 @default.
• W3133695493 cites W2944553601 @default.
• W3133695493 cites W2965689425 @default.
• W3133695493 cites W2972868802 @default.
• W3133695493 cites W3005161415 @default.
• W3133695493 cites W3042325035 @default.
• W3133695493 cites W3089744476 @default.
• W3133695493 cites W3090413504 @default.
• W3133695493 cites W3096606064 @default.
• W3133695493 doi "https://doi.org/10.1007/s00277-021-04471-6" @default.
• W3133695493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7930524" @default.
• W3133695493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33661333" @default.
• W3133695493 hasPublicationYear "2021" @default.
• W3133695493 type Work @default.
• W3133695493 sameAs 3133695493 @default.
• W3133695493 citedByCount "9" @default.
• W3133695493 countsByYear W31336954932021 @default.
• W3133695493 countsByYear W31336954932022 @default.
• W3133695493 countsByYear W31336954932023 @default.
• W3133695493 crossrefType "journal-article" @default.
• W3133695493 hasAuthorship W3133695493A5011277749 @default.
• W3133695493 hasAuthorship W3133695493A5017935090 @default.
• W3133695493 hasAuthorship W3133695493A5034255404 @default.
• W3133695493 hasAuthorship W3133695493A5037701749 @default.
• W3133695493 hasAuthorship W3133695493A5038221843 @default.
• W3133695493 hasAuthorship W3133695493A5049045971 @default.
• W3133695493 hasAuthorship W3133695493A5049132694 @default.
• W3133695493 hasAuthorship W3133695493A5053623055 @default.
• W3133695493 hasAuthorship W3133695493A5058893012 @default.
• W3133695493 hasAuthorship W3133695493A5075222101 @default.
• W3133695493 hasBestOaLocation W31336954931 @default.
• W3133695493 hasConcept C126322002 @default.
• W3133695493 hasConcept C141071460 @default.
• W3133695493 hasConcept C197934379 @default.
• W3133695493 hasConcept C2776694085 @default.
• W3133695493 hasConcept C2777063308 @default.
• W3133695493 hasConcept C2777408962 @default.
• W3133695493 hasConcept C2778041864 @default.
• W3133695493 hasConcept C2778729363 @default.
• W3133695493 hasConcept C2778850193 @default.
• W3133695493 hasConcept C2781413609 @default.
• W3133695493 hasConcept C2911091166 @default.
• W3133695493 hasConcept C71924100 @default.
• W3133695493 hasConcept C90924648 @default.
• W3133695493 hasConceptScore W3133695493C126322002 @default.
• W3133695493 hasConceptScore W3133695493C141071460 @default.
• W3133695493 hasConceptScore W3133695493C197934379 @default.
• W3133695493 hasConceptScore W3133695493C2776694085 @default.
• W3133695493 hasConceptScore W3133695493C2777063308 @default.
• W3133695493 hasConceptScore W3133695493C2777408962 @default.
• W3133695493 hasConceptScore W3133695493C2778041864 @default.
• W3133695493 hasConceptScore W3133695493C2778729363 @default.
• W3133695493 hasConceptScore W3133695493C2778850193 @default.
• W3133695493 hasConceptScore W3133695493C2781413609 @default.
• W3133695493 hasConceptScore W3133695493C2911091166 @default.
• W3133695493 hasConceptScore W3133695493C71924100 @default.
• W3133695493 hasConceptScore W3133695493C90924648 @default.
• W3133695493 hasIssue "5" @default.
• W3133695493 hasLocation W31336954931 @default.
• W3133695493 hasLocation W31336954932 @default.
• W3133695493 hasLocation W31336954933 @default.
• W3133695493 hasOpenAccess W3133695493 @default.
• W3133695493 hasPrimaryLocation W31336954931 @default.
• W3133695493 hasRelatedWork W1196768483 @default.
• W3133695493 hasRelatedWork W2020898191 @default.
• W3133695493 hasRelatedWork W2102925359 @default.
• W3133695493 hasRelatedWork W2128269008 @default.
• W3133695493 hasRelatedWork W2294565310 @default.
• W3133695493 hasRelatedWork W2309839179 @default.
• W3133695493 hasRelatedWork W2371995996 @default.
• W3133695493 hasRelatedWork W4247120321 @default.
• W3133695493 hasRelatedWork W4286829519 @default.
• W3133695493 hasRelatedWork W4311331895 @default.

• next